Gene editing research

Gene editing research

He Jiankui, a biology professor at the Southern University of Science and Technology in Shenzen, China, speaks at the Second International Summit on Human Genome Editing in Hong Kong on Nov. 28, 2018. He claimed to have produced the world's first genetically edited baby. (Kyodo) ==Kyodo

  • Product Code
  • ILEA000145394
  • Registered date
  • 2018/11/29 20:53:02
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2018 Kyodo News
  • Media size
  • 2533 × 3471 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 1.05(MB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Hong Kong Global Talent Summit

    Hong Kong Global Talent Summit

    A general view is showing the BOCHK booth at the Global Talent Summit in Hong Kong, on May 3, 2024. (Photo by Vernon Yuen/NurPhoto)
      The First Fully Automatic Single-cell Proteome Analysis Platform in China

      The First Fully Automatic Single-cell Proteome Analysis Platform in China

      A researcher is watching the results of protein analysis on a fully automated single-cell proteome analysis platform at the Hangzhou International Science and Innovation Center Laboratory of Zhejiang University in Hangzhou, Zhejiang Province, China, on March 7, 2024. (Photo by Costfoto/NurPhoto)
        The First Fully Automatic Single-cell Proteome Analysis Platform in China

        The First Fully Automatic Single-cell Proteome Analysis Platform in China

        A researcher is watching the results of protein analysis on a fully automated single-cell proteome analysis platform at the Hangzhou International Science and Innovation Center Laboratory of Zhejiang University in Hangzhou, Zhejiang Province, China, on March 7, 2024. (Photo by Costfoto/NurPhoto)
          The First Fully Automatic Single-cell Proteome Analysis Platform in China

          The First Fully Automatic Single-cell Proteome Analysis Platform in China

          An instrument associated with a fully automated single-cell proteome analysis platform is being pictured in the laboratory of Hangzhou International Science and Innovation Center of Zhejiang University in Hangzhou, Zhejiang Province, China, on March 7, 2024. (Photo by Costfoto/NurPhoto)
            The First Fully Automatic Single-cell Proteome Analysis Platform in China

            The First Fully Automatic Single-cell Proteome Analysis Platform in China

            A researcher is watching the results of protein analysis on a fully automated single-cell proteome analysis platform at the Hangzhou International Science and Innovation Center Laboratory of Zhejiang University in Hangzhou, Zhejiang Province, China, on March 7, 2024. (Photo by Costfoto/NurPhoto)
              CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

              CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

              (240220) -- BEIJING, Feb. 20, 2024 (Xinhua) -- Zhu Rui attends a video conference on his way to a branch office of Vivolight in Xi'an, northwest China's Shaanxi Province, Jan. 18, 2024. On Feb. 18, the first working day after China's Spring Festival holiday, Zhu Rui, founder of medical device company Vivolight, came to the catheter operating room of Beijing Anzhen Hospital to learn about the use of OCT equipment produced by his company. OCT, or optical coherence tomography technology, allows doctors to examine patients and display real-time three-dimensional images where the catheter passes, providing guide for surgery. Since graduating from Tsinghua University in 2006, Zhu has been engaged in OCT related research and product development. His role has changed from a student, a researcher to an entrepreneur. While studying in Beijing, Zhu built an OCT system for ophthalmology. While studying for his PhD in Hong Kong, he realized the potential value of OCT technology in cardiovascular surgery. In 2012,
                CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

                CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

                (240220) -- BEIJING, Feb. 20, 2024 (Xinhua) -- Zhu Rui (R) talks with his colleague at a branch office of Vivolight in Xi'an, northwest China's Shaanxi Province, Jan. 19, 2024. On Feb. 18, the first working day after China's Spring Festival holiday, Zhu Rui, founder of medical device company Vivolight, came to the catheter operating room of Beijing Anzhen Hospital to learn about the use of OCT equipment produced by his company. OCT, or optical coherence tomography technology, allows doctors to examine patients and display real-time three-dimensional images where the catheter passes, providing guide for surgery. Since graduating from Tsinghua University in 2006, Zhu has been engaged in OCT related research and product development. His role has changed from a student, a researcher to an entrepreneur. While studying in Beijing, Zhu built an OCT system for ophthalmology. While studying for his PhD in Hong Kong, he realized the potential value of OCT technology in cardiovascular surgery. In 2012, he gave u
                  CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

                  CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

                  (240220) -- BEIJING, Feb. 20, 2024 (Xinhua) -- Zhu Rui (R) talks with his partner Dr. Mi Lei in Xi'an, northwest China's Shaanxi Province, Jan. 19, 2024. On Feb. 18, the first working day after China's Spring Festival holiday, Zhu Rui, founder of medical device company Vivolight, came to the catheter operating room of Beijing Anzhen Hospital to learn about the use of OCT equipment produced by his company. OCT, or optical coherence tomography technology, allows doctors to examine patients and display real-time three-dimensional images where the catheter passes, providing guide for surgery. Since graduating from Tsinghua University in 2006, Zhu has been engaged in OCT related research and product development. His role has changed from a student, a researcher to an entrepreneur. While studying in Beijing, Zhu built an OCT system for ophthalmology. While studying for his PhD in Hong Kong, he realized the potential value of OCT technology in cardiovascular surgery. In 2012, he gave up his doctoral studies
                    CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

                    CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

                    (240220) -- BEIJING, Feb. 20, 2024 (Xinhua) -- Zhu Rui (R) tests a new generation of OCT equipment at a laboratory of a branch office of Vivolight in Xi'an, northwest China's Shaanxi Province, Jan. 18, 2024. On Feb. 18, the first working day after China's Spring Festival holiday, Zhu Rui, founder of medical device company Vivolight, came to the catheter operating room of Beijing Anzhen Hospital to learn about the use of OCT equipment produced by his company. OCT, or optical coherence tomography technology, allows doctors to examine patients and display real-time three-dimensional images where the catheter passes, providing guide for surgery. Since graduating from Tsinghua University in 2006, Zhu has been engaged in OCT related research and product development. His role has changed from a student, a researcher to an entrepreneur. While studying in Beijing, Zhu built an OCT system for ophthalmology. While studying for his PhD in Hong Kong, he realized the potential value of OCT technology in cardiovascu
                      CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

                      CHINA-BEIJING-OCT TECHNOLOGY-ENTREPRENEURSHIP (CN)

                      (240220) -- BEIJING, Feb. 20, 2024 (Xinhua) -- Zhu Rui (R) learns about the use of OCT equipment at Beijing Anzhen Hospital in Beijing, capital of China, Feb. 18, 2024. On Feb. 18, the first working day after China's Spring Festival holiday, Zhu Rui, founder of medical device company Vivolight, came to the catheter operating room of Beijing Anzhen Hospital to learn about the use of OCT equipment produced by his company. OCT, or optical coherence tomography technology, allows doctors to examine patients and display real-time three-dimensional images where the catheter passes, providing guide for surgery. Since graduating from Tsinghua University in 2006, Zhu has been engaged in OCT related research and product development. His role has changed from a student, a researcher to an entrepreneur. While studying in Beijing, Zhu built an OCT system for ophthalmology. While studying for his PhD in Hong Kong, he realized the potential value of OCT technology in cardiovascular surgery. In 2012, he gave up his do